Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.

Stephano Del PratoJahoon KangMichael E TrautmannJohn StewartChristopher H SorliMichael DerwahlAlfonso SotoKun-Ho Yoon

Published in: Diabetes, obesity & metabolism (2020)

Efpeglenatide once monthly (following once-weekly titration) has significant benefits with regard to HbA1c and weight reduction versus placebo in patients with T2D. Further studies are needed to evaluate the long-term efficacy and safety of efpeglenatide once monthly.

Keyphrases

placebo controlled
double blind
phase iii
phase ii
clinical trial
study protocol
phase ii study
open label
physical activity
weight loss
squamous cell carcinoma
radiation therapy
weight gain
body weight